HALOZYME THERAPEUTICS, INC.
For the period ended Sep 30, 2025. Filed Nov 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In February 2024, our Board of Directors authorized a new capital return program to repurchase up to $750.0 million of our outstanding common stock.
The table below sets forth information regarding repurchases during the three months ended September 30, 2025:
| Period · Total Number of Shares Purchased · Average Price paid per share (1) · Total Number of Shares Purchased as Part of Publicly Announced Programs · Approximate Dollar Value of Shares That May Yet Be purchased under the Programs (in thousands) | |||||
|---|---|---|---|---|---|
| July 1, 2025 through July 31, 2025 | 725,514 | $53.59 | 725,514 | $157,629 | |
| August 1, 2025 through August 31, 2025 | — | $— | — | $157,629 | |
| September 1, 2025 through September 30, 2025 | — | $— | — | $157,629 | |
| Total | 725,514 | 725,514 | |||
(1) Included in the total cost of shares purchased is a commission fee of $0.02 per share.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.